Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 16/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 14/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CSF1R | P07333 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.54 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21386612 | 0.89 | FGFR1 (0.57) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL21756514 | 0.85 | FGFR4 (0.68) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL21756513 | 0.82 | FGFR1 (0.65) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL21386705 | 0.82 | FGFR1 (0.59) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL21756566 | 0.80 | FGFR4 (0.59) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL21756512 | 0.79 | FGFR4 (0.47) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL21756574 | 0.78 | FGFR4 (0.71) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL21756507 | 0.78 | FGFR1 (0.57) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL20330736 | 0.77 | FGFR1 (0.79) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 | |
| SCHEMBL30045331 | 0.77 | FGFR1 (0.79) | FGFR1FGFR4CYP1A2CSF1RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2021-05-18 | — | — | US | disclosed |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008292-B2 | FGFR4 inhibitor and preparation method and use thereof | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR4 1/4885CYP1A2 1183/4885 |
| US-20200062716-A1 | FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF | FGFR4, FGFR1, FGFR2 | FGFR1 2/4885FGFR4 1/4885CYP1A2 1183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.